An update on the long-acting insulin analogue glargine

被引：26
|
作者：
Thisted, Henriette
Johnsen, Soren Paaske
Rungby, Jorgen
机构：
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Endocrinol C, DK-8000 Aarhus C, Denmark
[3] Univ Aarhus, Dept Pharmacol, Aarhus, Denmark
来源：
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2006年 / 99卷 / 01期
关键词：
D O I：
10.1111/j.1742-7843.2006.pto_352.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
For both type 1 and type 2 diabetes, tight glycaemic control is vital to reduce the risk of long-term complications. However, this must be achieved with minimal risk of hypoglycaemia. Glargine is a new long-acting insulin analogue with an action profile designed to overcome this and has now been in clinical use for a number of years. In many countries glargine is widely used. Here we present an update on the clinical information available on glargine with respect to glycaemic control, the risk of hypoglycaemia and quality of life in both type 1 and type 2 diabetes.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 50 条
  • [31] Development of Cagrilintide, a Long-Acting Amylin Analogue
    Kruse, Thomas
    Hansen, Jakob Lerche
    Dahl, Kirsten
    Schaffer, Lauge
    Sensfuss, Ulrich
    Poulsen, Christian
    Schlein, Morten
    Hansen, Ann Maria Kruse
    Jeppesen, Claus Bekker
    de la Cour, Charlotta Dornonville
    Clausen, Trine Ryberg
    Johansson, Eva
    Fulle, Simone
    Skyggebjerg, Rikke Bjerring
    Raun, Kirsten
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (15) : 11183 - 11194
  • [32] Insulin detemir: A long-acting insulin product
    Jones, Melissa C.
    Patel, Mallika
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (24) : 2466 - 2472
  • [33] Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update
    Pedersen-Bjergaard, Ulrik
    Fabricius, Therese W.
    Thorsteinsson, Birger
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (16) : 2251 - 2259
  • [34] EARLY LONG-ACTING INSULIN ANALOGUE ADMINISTRATION DURING ACUTE DIABETIC KETOACIDOSIS IN CHILDREN
    Singh, Kalpana
    Diaz, Alejandro
    Blyumin, Gabriella
    Totapally, Balagangadhar
    Martinez, Paul
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 544 - 544
  • [35] The Non-Human Primate in Safety Assessment of a Bifunctional Long-Acting Insulin Analogue
    Jensen, Vivi F. H.
    Jensen, Nikolai K.
    Schefe, Line H.
    Sigh, Jens
    Akintomide, Akinyemi
    Kaaber, Kari
    Moesgaard, Sophia G.
    Pedersen, Mona H.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2023, 42 (03) : 254 - 268
  • [36] Time-action profile of the long-acting insulin analogue HOE901.
    Linkeschowa, R
    Heise, T
    Rave, K
    Hompesch, B
    Heinemann, L
    DIABETOLOGIA, 1999, 42 : A234 - A234
  • [37] Effect of the long-acting insulin analogue detemir on IGF-I axis in humans
    Porcellati, E.
    Candeloro, P.
    Rossetti, P.
    Fanelli, C. G.
    Busciantella, N. Ricci
    Ghigo, E.
    Bolli, G. B.
    DIABETOLOGIA, 2008, 51 : S82 - S82
  • [38] Time-action profile of the long-acting insulin analogue HOE901
    Linkeschowa, R
    Heise, T
    Rave, K
    Hompesch, B
    Sedlack, M
    Heinemann, L
    DIABETES, 1999, 48 : A97 - A97
  • [39] When to take the long-acting insulin?
    不详
    DIABETES OBESITY & METABOLISM, 2003, 5 (06): : 471 - 471
  • [40] Long-acting insulin analogs and cancer
    Sciacca, L.
    Vella, V.
    Frittitta, L.
    Tumminia, A.
    Manzella, L.
    Squatrito, S.
    Belfiore, A.
    Vigneri, R.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2018, 28 (05) : 436 - 443
12345